Dermapharm's bold share buyback revives investor confidence after years of stagnation

A 10% premium buyback offer lured 4.8 million shares—far beyond Dermapharm's plan. Can this move finally break the three-year stock slump?

, and Administrator

2026 April 11 . 12:09 AM

1 min read

The image shows a blue background with text and a logo that reads "19 million Americans will save an estimated $400 per year on prescription drug costs".

Berlin – After years of aggressive acquisitions, Dermapharm is taking a breather—and is now buying back its own shares.

The company had announced plans to repurchase up to 4.3 million shares, equivalent to nearly 8% of its share capital. In the end, around 4.8 million shares were tendered, meaning shareholders will now be accommodated on a pro-rata basis.

Dermapharm offered €42 per share, a 10% premium over the stock's price on the record date. The move has helped further stabilize the share price, which—despite the company's string of acquisitions in recent years and repeated share purchases by founder Wilhelm Beier—has largely stagnated over the past three years. At its pandemic peak, the stock had surged to €90, buoyed by Dermapharm's role in bottling BioNTech's COVID-19 vaccine.

The company went public in 2018, with Beier retaining nearly 80% of the shares. Key acquisitions have included Strathmann (2018), Allergopharma (2020), Arkopharma and C3 (2022), and Mucos (2025). The group also comprises Anton Hübner and Euromed, along with a stake in Wellster Healthtech. However, its reimport subsidiary, Axicorp, has recently faced challenges.